SI9520059A - Compositions and treatment for multiple sclerosis. - Google Patents

Compositions and treatment for multiple sclerosis. Download PDF

Info

Publication number
SI9520059A
SI9520059A SI9520059A SI9520059A SI9520059A SI 9520059 A SI9520059 A SI 9520059A SI 9520059 A SI9520059 A SI 9520059A SI 9520059 A SI9520059 A SI 9520059A SI 9520059 A SI9520059 A SI 9520059A
Authority
SI
Slovenia
Prior art keywords
peptide
amino acid
mbp
acid residues
ifn
Prior art date
Application number
SI9520059A
Other languages
English (en)
Slovenian (sl)
Inventor
Di-Hwei Hsu
Dawn Smilek
Jia Dong Shi
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of SI9520059A publication Critical patent/SI9520059A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI9520059A 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis. SI9520059A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24124694A 1994-05-10 1994-05-10
US32822494A 1994-10-25 1994-10-25

Publications (1)

Publication Number Publication Date
SI9520059A true SI9520059A (en) 1997-08-31

Family

ID=26934122

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9520059A SI9520059A (en) 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis.

Country Status (11)

Country Link
EP (1) EP0758902A1 (ja)
JP (1) JPH10500109A (ja)
AU (1) AU2470595A (ja)
CA (1) CA2189990A1 (ja)
CZ (1) CZ329596A3 (ja)
HU (1) HUT76099A (ja)
IL (1) IL113661A0 (ja)
PL (1) PL317197A1 (ja)
SI (1) SI9520059A (ja)
SK (1) SK145896A3 (ja)
WO (1) WO1995030435A2 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT77047A (hu) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
AU5671196A (en) * 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
EP0939826A2 (en) * 1996-08-15 1999-09-08 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
CN102784385B (zh) * 2000-08-21 2015-11-25 阿皮托普技术(布里斯托尔)有限公司 肽选择方法
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
CN1656222B (zh) 2002-03-27 2011-11-30 艾格拉治疗公司 反义iap核碱基寡聚物及其应用
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212358T1 (de) * 1992-04-09 2002-02-15 Autoimmune Inc Unterdrückung der proliferation von t-zellen mittels peptidfragmenten des basischen proteins aus myelin
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease

Also Published As

Publication number Publication date
WO1995030435A2 (en) 1995-11-16
AU2470595A (en) 1995-11-29
CA2189990A1 (en) 1995-11-16
EP0758902A1 (en) 1997-02-26
CZ329596A3 (en) 1997-05-14
SK145896A3 (en) 1997-05-07
PL317197A1 (en) 1997-03-17
HUT76099A (en) 1997-06-30
JPH10500109A (ja) 1998-01-06
WO1995030435A3 (en) 1995-12-07
IL113661A0 (en) 1995-08-31
HU9603116D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
AU688214B2 (en) Method for treatment of autoimmune diseases using interferon-TAU
Teitelbaum et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy
Bakhiet et al. Depletion of CD8+ T cells suppresses growth of Trypanosoma brucei brucei and interferon‐gamma) production in infected rats
SI9520059A (en) Compositions and treatment for multiple sclerosis.
US5756449A (en) Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
US8771689B2 (en) Alpha B-crystallin as a therapy for ischemia or inflammation
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
Miller et al. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases
JP2010512403A (ja) 炎症の治療法としてのαＢクリスタリン
US6790447B1 (en) Peptides for treatment of autoimmune diseases
Abromson-Leeman et al. T cell responses to myelin basic protein in experimental autoimmune encephalomyelitis-resistant BALB/c mice
KR100333148B1 (ko) 당뇨질환예방제및치료제로서사용되는Vα14Jα281을함유하는가용성T-세포수용체α쇄및유도체
CA1290687C (en) Process for treatment of allergies
US6265374B1 (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
CA2076650C (en) Roquinimex for treating hiv infections
JP2007500693A (ja) 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
Jung et al. Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN.
AU684713B2 (en) Peptide T and related peptides in the treatment of inflammatory bowel disease
Skurkovich et al. A disturbance of interferon synthesis with the hyperproduction of unusual kinds of interferon can trigger autoimmune disease and play a pathogenetic role in AIDS: the removal of these interferons can be therapeutic
Skurkovich et al. A disturbance of interferon synthesis with the hyperproduction of unusual kinds of interferon can trigger autoimmune disease and play a pathogenetic role in AIDS: the removal of these interferons can be therapeutic
HRP20040071A2 (en) Use of il-18 inhibitors in hypersensitivity disorders
NZ256237A (en) Tolerizing t-cells to an antigen with a peptide
Bocci What roles have anti-interferon antibodies in physiology and pathology?
Savion et al. Acute immunosuppression and syngeneic bone marrow transplantation in ocular autoimmunity abort disease, but do not result in induction of long-term protection
Thurau et al. Immunomodulatory therapy in uveitis